Eduard Gorina, M.D. joined Pliant in 2018 as vice president of clinical development to oversee the execution of Pliant’s trials in multiple fibrotic diseases. Previously, he was executive director of clinical development at FibroGen, where he managed early and late-stage clinical programs for fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and Duchenne muscular dystrophy. Dr. Gorina also held senior director roles in clinical science at InterMune, where he played a key role in the development and filing of the NDA for the first therapy approved for patients with IPF (ESBRIET®, pirfenidone marketed by Roche), and at Portola Pharmaceuticals, where he was the clinical lead for the first-in-human study of a tyrosine kinase inhibitor. He started his pharmaceutical industry career at Bayer Biologicals, where he was global clinical leader for coagulation products, and later clinical project leader at Bayer Healthcare.
Dr. Gorina received his master’s in bioengineering from the Universitat Politècnica de Catalunya, his medical license from the Universitat Autònoma de Barcelona, and his training in clinical pharmacology at the pharmacology unit of Hospital Sant Pau in Barcelona.